Data presented at ASCO show Galleri detected more early-stage cancers than all existing UK screening programs combined and sharply increased diagnoses in a US real-world study; researchers stress it does not replace standard screening and survival benefits remain unproven

However, an increase in the detection of stage I/II cancers was observed

GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

The test is ‘feasible at scale’ on the NHS, say researchers

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

A pioneering blood test that can detect more than 50 cancers before symptoms appear could save tens of thousands of lives a year, promising new research suggests.

A major clinical trial involving 142,000 NHS patients revealed that the Galleri blood test for detecting over 50 cancers failed to reduce late-stage cancer diagnoses.

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable…

Data presented at ASCO show Galleri detected more early-stage cancers than all existing UK screening programs combined and sharply increased diagnoses in a US real-world study;…